Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.

ABSTRACT:

Background and aims

There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients.

Methods

We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis.

Results

We identified six eligible Crohn's disease and seven eligible ulcerative colitis trials that randomised over 1900 participants per disease cohort to infliximab or vedolizumab. In the Crohn's disease and ulcerative colitis cohorts, infliximab yielded better efficacy than vedolizumab for all analysed outcomes (CDAI-70, CDAI-100 responses, and clinical remission for Crohn's disease and clinical response and clinical remission for ulcerati

SUBMITTER: Peyrin-Biroulet L 

PROVIDER: S-EPMC9178865 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature